176 related articles for article (PubMed ID: 16609154)
1. Hepatitis C: changing genotype distribution with important implications for patient management.
van Soest H; Boland GJ; van Erpecum KJ
Neth J Med; 2006 Apr; 64(4):96-9. PubMed ID: 16609154
[TBL] [Abstract][Full Text] [Related]
2. [Genetic diagnosis of hepatitis C virus infection].
Stańczak JJ
Pol Merkur Lekarski; 1999 Feb; 6(32):92-5. PubMed ID: 10337182
[TBL] [Abstract][Full Text] [Related]
3. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
Nattermann J; Vogel M; Nischalke HD; Danta M; Ahlenstiel G; Michalk M; Sauerbruch T; Rockstroh JK; Spengler U;
AIDS; 2008 Jul; 22(11):1287-92. PubMed ID: 18580607
[TBL] [Abstract][Full Text] [Related]
4. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
[TBL] [Abstract][Full Text] [Related]
6. Genotype distribution amongst hepatitis C patients in The Netherlands.
de Vries MJ; te Rijdt B; van Nieuwkerk CM
Neth J Med; 2006 Apr; 64(4):109-13. PubMed ID: 16609157
[TBL] [Abstract][Full Text] [Related]
7. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
8. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
[TBL] [Abstract][Full Text] [Related]
9. [Molecular epidemiology of chronic hepatitis C (HCV) virus].
Nitkiewicz J
Przegl Epidemiol; 2004; 58(3):413-21. PubMed ID: 15730005
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
11. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
13. Current therapy of hepatitis C.
de Knegt RJ
Scand J Gastroenterol Suppl; 2006; (243):65-9. PubMed ID: 16782624
[TBL] [Abstract][Full Text] [Related]
14. Treatment predictors of a sustained virologic response in hepatitis B and C.
Kau A; Vermehren J; Sarrazin C
J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
[TBL] [Abstract][Full Text] [Related]
15. Rapid virologic response: a new milestone in the management of chronic hepatitis C.
Poordad F; Reddy KR; Martin P
Clin Infect Dis; 2008 Jan; 46(1):78-84. PubMed ID: 18171217
[TBL] [Abstract][Full Text] [Related]
16. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment.
Irshad M; Ansari MA; Singh A; Nag P; Raghvendra L; Singh S; Badhal SS
Hepatogastroenterology; 2010; 57(104):1529-38. PubMed ID: 21443116
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2.
Sikuler E; Tur-Kaspa R; Shemer-Avni Y; Delgado J; Zilberman D; Fich A; Baruch Y; Hyam E
J Clin Gastroenterol; 2008 Jul; 42(6):730-3. PubMed ID: 18574394
[TBL] [Abstract][Full Text] [Related]
18. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C virus genotype 4: epidemiology and treatment].
Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
[No Abstract] [Full Text] [Related]
20. Treating patients with HCV genotype 1 and low viraemia: more than meets the eye.
Craxì A; Cammà C
J Hepatol; 2006 Jan; 44(1):4-7. PubMed ID: 16293337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
